newsfilter
← Latest News
Business Wire·

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney